WO2017106609A3 - Anticorps du pdgfr bêta - Google Patents

Anticorps du pdgfr bêta Download PDF

Info

Publication number
WO2017106609A3
WO2017106609A3 PCT/US2016/067115 US2016067115W WO2017106609A3 WO 2017106609 A3 WO2017106609 A3 WO 2017106609A3 US 2016067115 W US2016067115 W US 2016067115W WO 2017106609 A3 WO2017106609 A3 WO 2017106609A3
Authority
WO
WIPO (PCT)
Prior art keywords
beta antibody
antibody agents
pdgfr beta
pdgfrβ
bind
Prior art date
Application number
PCT/US2016/067115
Other languages
English (en)
Other versions
WO2017106609A2 (fr
Inventor
Dan Lu
Original Assignee
Kadmon Corporation, Llc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kadmon Corporation, Llc. filed Critical Kadmon Corporation, Llc.
Publication of WO2017106609A2 publication Critical patent/WO2017106609A2/fr
Publication of WO2017106609A3 publication Critical patent/WO2017106609A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

L'invention concerne des agents anticorps qui se lient au PDGFRβ. L'invention concerne également des acides nucléiques isolés codant pour des agents anticorps qui se lient au PDGFRβ, des vecteurs d'acides nucléiques et des cellules hôtes procaryotes ou eucaryotes comprenant de tels acides nucléiques isolés, ainsi que des compositions comprenant ces agents anticorps et des procédés d'utilisation de ceux-ci.
PCT/US2016/067115 2015-12-16 2016-12-16 Anticorps du pdgfr bêta WO2017106609A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562268424P 2015-12-16 2015-12-16
US62/268,424 2015-12-16

Publications (2)

Publication Number Publication Date
WO2017106609A2 WO2017106609A2 (fr) 2017-06-22
WO2017106609A3 true WO2017106609A3 (fr) 2017-08-03

Family

ID=59057824

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/067115 WO2017106609A2 (fr) 2015-12-16 2016-12-16 Anticorps du pdgfr bêta

Country Status (1)

Country Link
WO (1) WO2017106609A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021142086A1 (fr) 2020-01-08 2021-07-15 Synthis Therapeutics, Inc. Conjugués inhibiteurs d'alk5 et leurs utilisations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090053241A1 (en) * 2007-04-17 2009-02-26 Imclone Systems Incorporated PDGFRbeta-specific inhibitors
WO2009120922A2 (fr) * 2008-03-27 2009-10-01 Zymogenetics, Inc. Compositions et procédés pour inhiber pdgfr-bêta et vegf-a
US20100119511A1 (en) * 2008-10-31 2010-05-13 Biogen Idec Ma Inc. Light targeting molecules and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090053241A1 (en) * 2007-04-17 2009-02-26 Imclone Systems Incorporated PDGFRbeta-specific inhibitors
WO2009120922A2 (fr) * 2008-03-27 2009-10-01 Zymogenetics, Inc. Compositions et procédés pour inhiber pdgfr-bêta et vegf-a
US20110177074A1 (en) * 2008-03-27 2011-07-21 Sivakumar Pallavur V Compositions and methods for inhibiting pdgfrbeta and vegf-a
US20100119511A1 (en) * 2008-10-31 2010-05-13 Biogen Idec Ma Inc. Light targeting molecules and uses thereof

Also Published As

Publication number Publication date
WO2017106609A2 (fr) 2017-06-22

Similar Documents

Publication Publication Date Title
MX2018013139A (es) Composiciones detergentes y sus usos.
WO2016066756A3 (fr) Variants de protéase et polynucléotides les codant
WO2016066757A3 (fr) Variants de protéase et polynucléotides les codant
CA3010891A1 (fr) Brins d'acides nucleiques recombinogeniques in situ
PH12018501355A1 (en) Rsv f protein mutants
MX2017007731A (es) Composiciones de detergente, variantes de lipasa y polinucleotidos que codifican las mismas.
MX2017014125A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
EA201890630A1 (ru) Антитела против pd-1 и способы их применения
WO2016106159A8 (fr) Anticorps anti-pd-1
AU2017380488A8 (en) Polypeptides having lysozyme activity, polynucleotides encoding same and uses and compositions thereof
EP3950941A3 (fr) Variants polypeptidiques de la dnase
EP3741848A3 (fr) Variantes de protéases et polynucléotides les codant
WO2015024739A3 (fr) Compositions de détergent comprenant des variants de protéase
EP3741849A3 (fr) Variantes de protéases et polynucléotides les codant
EA201890565A1 (ru) Композиции и способы улучшения специфичности в геномной инженерии с применением рнк-направляемых эндонуклеаз
WO2014106015A3 (fr) Compositions protéiques à liaison multivalente
WO2015014790A3 (fr) Variants de protéase et polynucléotides les codant
MX2019000140A (es) Variantes de xilanasa y polinucleotidos que las codifican.
EP4273238A3 (fr) Compositions comprenant des polypeptides ayant une activité xylanase et des polypeptides ayant une activité arabinofuranosidase
WO2015196128A3 (fr) Molécules d'acide nucléique alternatives et leurs utilisations
WO2015196130A3 (fr) Molécules d'acide nucléique alternatives et leurs utilisations
BR112019011582A2 (pt) anticorpos e métodos de utilização dos mesmos
WO2016057951A3 (fr) Oligonucléotides crispr et édition de gènes
MX2016012479A (es) Miembros de unión al factor de necrosis tumoral (tnf) alfa.
WO2018081592A3 (fr) Compositions et procédés pour la production de composés

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16876751

Country of ref document: EP

Kind code of ref document: A2